Jan Reckweg
Clinical Researcher and Psychopharmacologist
Data updated
Research Footprint
Jan Reckweg appears in 16 tracked papers (2020–2026), most studied alongside Ayahuasca, Psilocybin and 5-MeO-DMT, across Neuroimaging & Brain Measures, Depressive Disorders and Healthy Volunteers.
Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).
Frequent co-authors: Johannes Ramaekers, Nathalie Mason and Stefan Toennes.
Publication Landscape
How the 16 papers Blossom tracks for Jan Reckweg line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Jan Reckweg's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 16 of 16 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Jan Reckweg publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Jan Reckweg publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Jan Reckweg is a clinical researcher and psychopharmacologist whose work focuses on the clinical pharmacology, safety profiling and experiential measurement of contemporary and classical psychedelics. He has co‑authored multiple phase 1 and phase 1/2 studies evaluating a vapourised 5‑methoxy‑N,N‑dimethyltryptamine formulation (GH001) in both healthy volunteers and patients with treatment‑resistant depression, including dose‑ranging safety and psychoactive‑effect characterisations and a phase 1/2 efficacy assessment. Reckweg has also contributed to comparative acute‑effects studies (for example 2C‑B versus psilocybin), investigations of structural brain differences associated with repeated ayahuasca use, and the development and evaluation of rapid assessment tools such as a peak‑experience scale for 5‑MeO‑DMT.
Key Impact
Notable for leading and co‑authoring early‑phase clinical investigations of short‑acting tryptamines (notably vaporised 5‑MeO‑DMT/GH001), and for contributions to safety, psychometric and neuroimaging research in contemporary psychedelic science.
Collaboration Network
23 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Jan Reckweg's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Jan Reckweg is associated with.